SAB Biotherapeutics (NASDAQ:SABS) Posts Quarterly Earnings Results, Misses Estimates By $0.15 EPS

SAB Biotherapeutics (NASDAQ:SABS) posted its quarterly earnings data on Tuesday. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15), FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SABBio said SAFEGUARD enrollment is on track, with Part A fully enrolled and Part B now actively enrolling across the U.S., Australia, New Zealand, the U.K. and Europe.
• The company received FDA written confirmation that C-peptide may be used as a surrogate endpoint for accelerated approval, which management described as a meaningful de-risking of the regulatory path.
• Phase I SAB-142 data continued to support the program, with management highlighting beta-cell preservation, T-cell exhaustion, and a favorable safety profile including no serum sickness and low or no immunogenicity.
• SABBio ended Q1 with $217.6 million in cash, cash equivalents and available-for-sale securities, which it says funds operations through 2028 and supports SAFEGUARD plus pre-commercial work.
• The company also signed a multi-year manufacturing agreement with Emergent BioSolutions to support process development and both clinical and commercial production ahead of a potential launch.

SAB Biotherapeutics Price Performance

Shares of NASDAQ SABS traded down $0.07 during trading on Tuesday, hitting $3.66. The company had a trading volume of 359,968 shares, compared to its average volume of 645,977. The company has a market cap of $186.22 million, a P/E ratio of -1.58 and a beta of 0.55. SAB Biotherapeutics has a 52 week low of $1.60 and a 52 week high of $6.60. The business’s 50-day moving average is $3.87 and its 200 day moving average is $3.81. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.46 and a current ratio of 9.46.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new position in shares of SAB Biotherapeutics in the fourth quarter worth approximately $3,004,000. Millennium Management LLC acquired a new position in shares of SAB Biotherapeutics in the fourth quarter worth $1,212,000. Balyasny Asset Management L.P. purchased a new stake in shares of SAB Biotherapeutics during the 4th quarter worth about $1,778,000. ADAR1 Capital Management LLC lifted its stake in SAB Biotherapeutics by 75.6% in the fourth quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after acquiring an additional 11,344 shares during the last quarter. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at $322,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. HC Wainwright decreased their price target on SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. Wall Street Zen lowered SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Zacks Research cut SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Rodman & Renshaw reaffirmed a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a report on Monday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, SAB Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $10.50.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.